(CercleFinance.com) – Novartis on Monday unveiled new positive data over a period of 48 weeks as part of its phase III clinical study conducted in patients with paroxysmal nocturnal hemoglobinuria (PNH).
The Swiss biopharmaceutical group indicates that these results show sustained effectiveness and long-term safety of use of Fabhalta in this blood disease, which results in particular in arterial and venous thromboses.
According to the laboratory, the drug made it possible to sustainably increase the hemoglobin level to a level close to normal, to avoid blood transfusions and to improve the fatigue of patients in the majority of cases.
At the same time, patients who switched from anti-C5 to Fabhalta-based treatment between weeks 24 and 48 achieved results comparable to those recorded in the Fabhalta group after 24 weeks, including in the avoidance of transfusions and obtaining hemoglobin levels close to normal.
For the record, Fabhalta was recently approved by the US FDA for the treatment of paroxysmal nocturnal hemoglobinuria.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
